Rasuvo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to control the symptoms of severe, disabling psoriasis that is resistant to treatment. Rasuvo may be prescribed in adult cases where other treatments are not effective. Rasuvo is also referred to by its drug name, methotrexate.
Rasuvo is an immunomodulator, or a drug that modulates the immune system. Rasuvo is also referred to as a disease-modifying antirheumatic drug (DMARD) or a slow-acting antirheumatic drug (SAARD). It is an antimetabolite that blocks the synthesis of purine, a protein the body needs to produce lymphocytes. Lymphocytes are a type of white blood cell active in the immune system. Rasuvo is believed to work by interfering with lymphocytes and preventing them from attacking the tissues.
How do I take it?
Prescribing information states that Rasuvo is administered once a week by subcutaneous injection.
Rasuvo comes in the form of a single-dose auto-injector.
The FDA-approved label for Rasuvo lists common side effects including nausea, abdominal pain, indigestion, mouth and stomach ulcers, rash, cold symptoms, diarrhea, liver function test abnormalities, vomiting, headache, bronchitis, low blood cell counts, hair loss, dizziness, photosensitivity, and burning of skin lesions.
Rare but serious side effects listed for Rasuvo include toxic effects on organ systems, fetal harm, and impairment of the reproductive system.
For more details about this treatment, visit:
Rasuvo — Medexus Pharma